Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 686

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Rosenfield, Kenneth, Jaff, Michael R., White, Christopher J., Rocha-Singh, Krishna, Mena-Hurtado, Carlos, Metzger, D. Christopher, Brodmann, Marianne, Pilger, Ernst, Zeller, Thomas, Krishnan, Prakash, Gammon, Roger, Müller-Hülsbeck, Stefan, Nehler, Mark R., Benenati, James F., Scheinert, Dierk·2015·New England Journal of Medicine

Abstract

BACKGROUND: The treatment of peripheral artery disease with percutaneous transluminal angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated angioplasty balloons deliver antiproliferative agents directly to the artery, potentially improving vessel patency by reducing restenosis. METHODS: In this single-blind, randomized trial conducted at 54 sites, we assigned, in a 2:1 ratio, 476 patients with symptomatic intermittent claudication or ischemic pain while at rest and angiographically significant atherosclerotic lesions to angioplasty with a paclitaxel-coated balloon or to standard angioplasty. The primary efficacy end point was primary patency of the target lesion at 12 months (defined as freedom from binary restenosis or from the need for target-lesion revascularization). The primary safety end point was a composite of freedom from perioperative death from any cause and freedom at 12 months from limb-related death (i.e., death from a medical complication related to a limb), amputation, and reintervention. RESULTS: The two groups were well matched at baseline; 42.9% of the patients had diabetes, and 34.7% were current smokers. At 12 months, the rate of primary patency among patients who had undergone angioplasty with the drug-coated balloon was superior to that among patients who had undergone conventional angioplasty (65.2% vs. 52.6%, P=0.02). The proportion of patients free from primary safety events was 83.9% with the drug-coated balloon and 79.0% with standard angioplasty (P=0.005 for noninferiority). There were no significant between-group differences in functional outcomes or in the rates of death, amputation, thrombosis, or reintervention. CONCLUSIONS: Among patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloon resulted in a rate of primary patency at 12 months that was higher than the rate with angioplasty with a standard balloon. The drug-coated balloon was noninferior to the standard balloon with respect to safety. (Funded by Lutonix-Bard; LEVANT 2 ClinicalTrials.gov number, NCT01412541.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1406235

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 686

Metadata

Authors
Rosenfield, K., Jaff, M. R., White, C. J., Rocha-Singh, K., Mena-Hurtado, C., Metzger, D. C., Brodmann, M., Pilger, E., Zeller, T., Krishnan, P., Gammon, R., Müller-Hülsbeck, S., Nehler, M. R., Benenati, J. F., & Scheinert, D.
Venue
New England Journal of Medicine
Published
2015-07-09
Volume
373
Issue
2
Pages
145-153
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2118501388
Cited by
686
References
19
FWCI
66.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. https://app.cochat.ai/papers/10.1056/nejmoa1406235
The paper
Rosenfield, K., Jaff, M. R., White, C. J., Rocha-Singh, K., Mena-Hurtado, C., Metzger, D. C., Brodmann, M., Pilger, E., Zeller, T., Krishnan, P., Gammon, R., Müller-Hülsbeck, S., Nehler, M. R., Benenati, J. F., & Scheinert, D. (2015). Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1406235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.